Live Attenuated Leishmania donovani Centrin Gene-Deleted Parasites Induce IL-23-Dependent IL-17-Protective Immune Response against Visceral Leishmaniasis in a Murine Model

J Immunol. 2018 Jan 1;200(1):163-176. doi: 10.4049/jimmunol.1700674. Epub 2017 Nov 29.

Abstract

No vaccine exists against visceral leishmaniasis. To develop effective vaccines, we have previously reported protective role of live attenuated centrin gene-deleted Leishmania donovani (LdCen-/- ) parasites through induction of Th1 type immune response in mice, hamsters, and dogs. In this study, we specifically explored the role of Th17 cells in LdCen-/- -induced host protection in mice. Our results showed that compared with wild-type L. donovani infection, LdCen-/- parasites induce significantly higher expression of Th17 differentiation cytokines in splenic dendritic cells. There was also induction of IL-17 and its promoting cytokines in total splenocytes and in both CD4 and CD8 T cells following immunization with LdCen-/- Upon challenge with wild-type parasites, IL-17 and its differentiating cytokines were significantly higher in LdCen-/- -immunized mice compared with nonimmunized mice that resulted in parasite control. Alongside IL-17 induction, we observed induction of IFN-γ-producing Th1 cells as reported earlier. However, Th17 cells are generated before Th1 cells. Neutralization of either IL-17 or IFN-γ abrogated LdCen-/- -induced host protection further confirming the essential role of Th17 along with Th1 cytokines in host protection. Treatment with recombinant IL-23, which is required for stabilization and maintenance of IL-17, heightened Th17, and Tc17 responses in immunized mice splenocytes. In contrast, Th17 response was absent in immunized IL-23R-/- mice that failed to induce protection upon virulent Leishmania challenge suggesting that IL-23 plays an essential role in IL-17-mediated protection by LdCen-/- parasites. This study unveiled the role of IL-23-dependent IL-17 induction in LdCen-/- parasite-induced immunity and subsequent protection against visceral leishmaniasis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Animals, Genetically Modified
  • Female
  • Humans
  • Interleukin-17 / metabolism*
  • Interleukin-23 / metabolism*
  • Leishmania donovani / genetics
  • Leishmania donovani / immunology*
  • Leishmaniasis Vaccines / genetics
  • Leishmaniasis Vaccines / immunology*
  • Leishmaniasis, Visceral / immunology*
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Protozoan Proteins / genetics
  • Receptors, Interleukin / genetics
  • Th1 Cells / immunology*
  • Th1 Cells / parasitology
  • Th17 Cells / immunology*
  • Th17 Cells / parasitology
  • Vaccines, Attenuated / immunology

Substances

  • Interleukin-17
  • Interleukin-23
  • Leishmaniasis Vaccines
  • Protozoan Proteins
  • Receptors, Interleukin
  • Vaccines, Attenuated
  • interleukin-23 receptor, mouse